CLINUVEL excels in scientific research and development. We build on our global expertise to deliver long-term care and develop novel products for patients and consumers.
Our Mission
The CLINUVEL Group works to translate scientific concepts and breakthroughs into commercial products.
CLINUVEL excels in scientific research and development. We build on our global expertise to deliver long-term care and develop novel products for patients and consumers.
The CLINUVEL Group places much emphasis on its People and Environment as central to all of the Group’s working practice. CLINUVEL focuses its research and development on healthcare problems not yet addressed, aiming to deliver innovative medical solutions. Our products seek to prevent or treat acute and chronic medical conditions where no alternatives exist
Our Values
We work for those who have no alternatives: patients, physicians, and individuals at-risk.
We are selective of with whom we work, and invest time in the talent we employ. We aspire to create an environment where professionals are able to develop and grow. We aim to present skilled talent with early opportunities, responsibilities and accountability as part of training the next generation.
We strive to build international teams and operate on the basis of gender and ethnic equality. We wish to set an example of excellence in our industry.
We aim to be innovative in our approach and find solutions for unique, complex and previously neglected healthcare problems.
We are determined to remain leaders in our fields of expertise and be creative and diligent in all our endeavours. We admit errors, recognise our shortfalls, evaluate, analyse and learn to implement new findings.
In improving ourselves we strive to enhance the lives and quality of life of those we serve. We are vigilant not to become complacent and recognise that success can only come from the identification and mastering of obstacles.
Our staff are optimistic and focused.
We create, develop, advance, and offer healthcare products which are driven by medical need, consumer demand and a lack of available solutions.
Our technologies aim to add value beyond existing offerings.
We acknowledge that new technologies require regulatory environments to be primed and markets to be prepared for achieving widespread acceptance and adoption.
Our expertise spans the fields of optical physics, the interaction of light and human biology, and the potential of melanocortin drugs in acute care and life-threatening conditions. We specialise in skin and brain disorders. We are proficient in our understanding of acute, rare, and complex disorders. We advance our ideas and concepts and translate them into effective and practical solutions. We aim to grow our knowhow continuously and establish a learned community. Collaboratively we seek to excel in a multifaceted field to arrive at scientific breakthroughs.
We are conscious of the privilege to be productive during our professional lives.
We appreciate the significance of being able to function in good health and we value this gift every day. We aim to be sincere in our approach and represent data and facts. We act respectfully and do not harm others.
We value our colleagues and co-workers and cherish diversity, equality, respect and harmony. We are passionate towards our objectives and share empathy and compassion for all those we work to serve.
Our History
2023
CLINUVEL launches CYACÊLLE polychromatic screen, its first PhotoCosmetic product.
2020
CLINUVEL announces the development of PRÉNUMBRA® a non-solid (liquid) formulation of afamelanotide for the treatment of acute disorders.
2019
The US Food and Drug Administration (FDA) grants marketing authorization for SCENESSE® (afamelanotide) for adult erythropoietic protoporphyria (EPP) patients.
2014
The European Medicines Agency grants marketing authorisation for SCENESSE® (afamelanotide 16mg) for the prevention of phototoxicity in adult EPP patients.
2006
CLINUVEL conducts its first clinical trial of afamelanotide in adult EPP patients.
2005
A new management team refocuses CLINUVEL on the development of afamelanotide as a therapeutic.
1999-2001
An Australian team acquires the rights to the alpha-MSH analogue afamelanotide and lists on the Australian Securities Exchange.
1980s
A US team begins to investigate the properties of alpha-melanocyte stimulating hormone (alpha-MSH) and analogues for their potential as therapeutics.
Our Focus
We study melanocortins and their interaction with the body. We then look to turn this research into pharmaceutical and PhotoCosmetic products. Within this specialist field of medicine we have specialised further into products that work primarily with skin and the central nervous system. This research has lead to expertise in the following topics:
- The interaction of visible and UV light and human biology
- The family of peptides known as melanocortins and their analogues
- The effect of hormonal therapies on anti-inflammatory and nervous disorders
- Controlled-release pharmaceutical formulations
